These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 9471022)

  • 1. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(4):319-24. PubMed ID: 8658063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes.
    Hopf U; Berg T; König V; Küther S; Heuft HG; Lobeck H
    J Hepatol; 1996; 24(2 Suppl):67-73. PubMed ID: 8836892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
    Martinot-Peignoux M; Marcellin P; Pouteau M; Castelnau C; Boyer N; Poliquin M; Degott C; Descombes I; Le Breton V; Milotova V
    Hepatology; 1995 Oct; 22(4 Pt 1):1050-6. PubMed ID: 7557850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic relevance of hepatitis C virus genotype for responsiveness to interferon-alpha].
    Berg T; König V; Küther S; Heuft HG; Wittmann G; Lobeck H; Hopf U
    Z Gastroenterol; 1995 Aug; 33(8):426-30. PubMed ID: 7483733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.
    Tsubota A; Chayama K; Ikeda K; Yasuji A; Koida I; Saitoh S; Hashimoto M; Iwasaki S; Kobayashi M; Hiromitsu K
    Hepatology; 1994 May; 19(5):1088-94. PubMed ID: 8175130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.
    Hayashi J; Ohmiya M; Kishihara Y; Tani Y; Kinukawa N; Ikematsu H; Kashiwagi S
    Am J Gastroenterol; 1994 Dec; 89(12):2151-6. PubMed ID: 7977232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of lymphoblastoid interferon alpha for chronic hepatitis C (comparison of 9-MU and 6-MU doses). IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya University School of Medicine.
    Yoshioka K; Yano M; Kusakabe A; Hirofuji H; Fuji A; Kuriki J; Arao M; Murase K; Kidokoro R; Kakumu S
    Am J Gastroenterol; 1999 Jan; 94(1):164-8. PubMed ID: 9934749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
    Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
    Arase Y; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Kobayashi M; Sezaki H; Ikeda K; Kumada H
    Intervirology; 2004; 47(1):19-25. PubMed ID: 15044832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.